AUDENTES THERAPEUTICS, INC. Inactive Instrument
Audentes Therapeutics, Inc. Stock
Equities
US05070R1041
Biotechnology & Medical Research
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Krivoshik
PSD | President | - | - |
Morten Sogaard
COO | Chief Operating Officer | - | 22-04-30 |
Jason Schwartz
CTO | Chief Tech/Sci/R&D Officer | - | 22-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kush Parmar
BRD | Director/Board Member | 42 | 13-06-30 |
Alan Beggs
BRD | Director/Board Member | - | - |
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.26% | 104B | |
| +1.54% | 97.42B | |
| +0.79% | 22.2B | |
| -17.82% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.93% | 15.06B | |
| +3.51% | 13.98B | |
| +33.73% | 11.66B |
